Why does administering a COX-2 selective inhibitor, like celecoxib, reduce inflammation while increasing the risk of thrombotic events in a patient?

💡 Explanation

Selective COX-2 inhibitors disrupt the normal prostaglandin balance because they block the production of prostacyclin (PGI2), a vasodilator and inhibitor of platelet aggregation. Therefore, the relative increase in thromboxane A2, a vasoconstrictor and platelet aggregator, increases thrombotic risk rather than other prostaglandin pathways.

• During a stress test, why does diastolic blood pressure sometimes decrease even when cardiac output and heart rate increase?
• If a novel virus infects human lung cells, triggering massive chemokine release that overwhelms local immune regulation, which consequence follows?
• Which outcome results when defective uterine lining prevents implantation?
• If a patient experiences repeated low-dose allergen exposures without immediate anaphylaxis, why might the subsequent exposure trigger a more severe allergic reaction?
• Which mechanism explains why ovarian follicle atresia occurs during the reproductive cycle in humans?
• A patient with cirrhosis experiences elevated blood ammonia levels. Which mechanism explains why hyperammonemia occurs in liver failure?